# [KJ-TFC-005] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

> **NCT07662759** · PHASE3 · RECRUITING · sponsor: **Kukje Pharma** · enrollment: 188 (estimated)

## Conditions studied

- Glaucoma Open-Angle Primary
- Ocular Hypertension

## Interventions

- **DRUG:** TFC-003
- **DRUG:** TFC-003-R1
- **DRUG:** TFC-003-R2+TFC-003-R3

## Key facts

- **NCT ID:** NCT07662759
- **Lead sponsor:** Kukje Pharma
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-09
- **Primary completion:** 2027-03
- **Final completion:** 2027-06
- **Target enrollment:** 188 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662759, "[KJ-TFC-005] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07662759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*